Synex Medical

Cover Block

PUBLIC

Name	Synex Medical
Tagline	Developing non-invasive magnetic resonance devices to measure blood metabolites in real time. [Synex Medical]
Headquarters	Toronto, Canada
Founded	2017
Stage	Series A
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Series A (total disclosed ~$27,050,000)

Links

PUBLIC

• Website: https://synexmedical.com/
• LinkedIn: https://www.linkedin.com/company/synexmedical

Executive Summary

PUBLIC

Synex Medical is developing non-invasive magnetic resonance devices to measure blood metabolites in real time, a technical approach that, if validated, could fundamentally shift the paradigm for continuous health monitoring from reactive to predictive. The company's core bet is on miniaturizing magnetic resonance spectroscopy (MRS) into a compact device and a consumer-oriented wearable ring, aiming to measure glucose, lactate, ketones, and cholesterol without needles or blood draws [Perplexity Sonar Pro Brief, retrieved 2024]. Founded in 2017 by Ben Nashman while he was still in high school, the company's origin story is marked by an intense commitment to the hardware challenge, famously involving a customs incident where Nashman was detained for transporting an 80-pound magnet for a homemade MRI [TechCrunch, September 2024]. Nashman remains CEO, and the team has been bolstered by hires including a president with a background from WHOOP and senior scientists specializing in nuclear magnetic resonance (NMR) [Crunchbase, retrieved 2024] [LinkedIn, retrieved 2026].

Following a $5.25 million seed round in 2020, Synex secured a substantial C$21.8 million Series A in September 2024, indicating strong investor confidence in its novel approach to a historically difficult problem [Synex Medical, October 2020] [Osler, September 2024]. The business model combines hardware sales with a software layer for data insights, targeting both consumer health and professional use cases. Over the next 12-18 months, the key milestones to watch are the transition from research and development to a functional, clinically validated prototype, and the articulation of a clear regulatory pathway for what will be a medical device.

Data Accuracy: GREEN -- Core company facts and funding rounds confirmed by company announcements and legal filings; team details corroborated by LinkedIn and Crunchbase.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Series A (total disclosed ~$27,050,000)

Company Overview

PUBLIC

Synex Medical was founded in Toronto in 2017 by Ben Nashman, who began the venture while still in high school [Synex Medical]. The company's origin story is intertwined with its technical ambition; in 2024, Nashman recounted to TechCrunch an incident where he was detained by U.S. customs for transporting an 80-pound magnet intended for a homemade MRI device, a formative event that underscored the founder's early and intense commitment to miniaturizing magnetic resonance technology [TechCrunch, September 2024]. The company remains headquartered in Toronto, with a secondary presence in Boston noted on its LinkedIn profile [LinkedIn].

Key company milestones follow a steady cadence of technical development and capital formation. The first significant public milestone was a $5.25 million seed round in October 2020, led by Accomplice and Radical Ventures, which provided the initial capital to advance its non-invasive monitoring research [Synex Medical, October 2020]. This was followed nearly four years later by a C$21.8 million Series A financing in September 2024, which was reported as oversubscribed [Osler, September 2024]. The multi-year gap between rounds suggests a focus on deep technical development, a pattern consistent with the long R&D cycles typical of novel medical hardware.

Data Accuracy: GREEN -- Confirmed by company announcement, legal filing, and independent news report.

Product and Technology

MIXED Synex Medical's core proposition is a hardware platform that applies the physics of magnetic resonance to the problem of metabolic monitoring, aiming to replace blood draws and subcutaneous sensors with a non-invasive measurement. The company is developing compact, portable devices that use magnetic resonance spectroscopy (MRS) to measure blood metabolites like glucose, lactate, and ketones in real time, directly through the skin [Synex Medical, retrieved 2024]. The public-facing vision describes a future of predictive and personalized medicine enabled by continuous, molecular-level data [Synex Medical, retrieved 2024].

The product architecture appears to have two main expressions. First is a compact, handheld device designed for at-home or point-of-care use. Second, and more prominently featured in some databases, is a consumer-oriented wearable concept referred to as the "One Ring," which would pair with a smartphone app to deliver continuous biomarker updates and health insights [Perplexity Sonar Pro Brief, retrieved 2024]. The technology's claimed differentiation rests on being both needle-free and capable of multi-analyte detection, moving beyond single-parameter monitoring like glucose to offer a more comprehensive metabolic panel [Perplexity Sonar Pro Brief, retrieved 2024].

Public job postings provide inferred detail on the technical stack. Open roles for a Staff RF Engineer and a Senior DSP/ML Engineer suggest the system involves sophisticated radio-frequency hardware design and advanced signal processing to interpret the magnetic resonance data [Synex Medical, retrieved 2024]. A separate posting for a Principal MRS Scientist indicates ongoing research into the core spectroscopic methods [Synex Medical, retrieved 2024]. The company has not publicly announced a commercial launch date or a detailed product roadmap.

Data Accuracy: GREEN -- Core product claims are confirmed by the company's website and independent databases; technical inferences are drawn from active job postings.

Market Research

PUBLIC The market for non-invasive, continuous health monitoring is expanding beyond glucose to encompass a broader set of metabolic biomarkers, driven by consumer demand for proactive health management and the limitations of current single-parameter solutions. Synex Medical's proposition targets this emerging multi-metabolite segment, which sits at the intersection of consumer wearables, digital health, and clinical diagnostics.

Third-party market sizing for multi-metabolite, non-invasive monitoring is not yet widely established, but analogous segments provide a proxy for potential scale. The global continuous glucose monitoring (CGM) market, a direct single-parameter precursor, was valued at approximately $8.5 billion in 2023 and is projected to grow to over $19 billion by 2030, according to Grand View Research [Grand View Research, 2024]. The broader wearable medical devices market, which includes cardiac and neurological monitors, is forecast to exceed $83 billion by 2030 [Precedence Research, 2024]. These figures suggest a substantial addressable market for a device that can measure multiple biomarkers with the convenience of a wearable, potentially capturing share from both the CGM market and adjacent monitoring categories.

Key demand drivers for this category include the rising prevalence of metabolic disorders like diabetes and obesity, a growing consumer focus on quantified health and performance optimization, and an increasing shift toward value-based and preventative healthcare models. The technology's proposed ability to measure lactate, for instance, could appeal to athletic performance monitoring, while ketone and cholesterol tracking addresses broader metabolic health concerns. A significant tailwind is the regulatory and reimbursement evolution for digital health tools, though this remains a complex and region-specific landscape.

Regulatory pathways present a primary macro consideration. Any device making health claims, particularly for disease management, will require clearance from bodies like the U.S. Food and Drug Administration (FDA) or Health Canada. The process for novel diagnostic hardware is typically lengthy and costly, representing a significant gating factor to commercial launch. Furthermore, the company must navigate data privacy regulations (HIPAA, GDPR) and establish clinical validity for each biomarker it claims to measure, a step that requires rigorous peer-reviewed studies.

CGM Market 2023 | 8.5 | $B
CGM Market 2030 | 19.1 | $B
Wearable Medical Devices Market 2030 | 83.4 | $B

The chart illustrates the substantial market trajectories of adjacent sectors. The growth in CGM, a $19 billion market by 2030, represents the most direct demand proxy for glucose monitoring, while the larger wearable medical device figure underscores the expansive potential for multi-parameter health tracking. Synex's success hinges on capturing a portion of this growth by convincing users and payors that its multi-metabolite data provides superior actionable insight compared to existing single-sensor solutions.

Data Accuracy: YELLOW -- Market sizing figures are drawn from third-party analyst reports for analogous sectors (CGM, wearable medical devices), not for the specific multi-metabolite monitoring niche. Demand drivers and regulatory considerations are based on general industry analysis.

Competitive Landscape

MIXED Synex Medical positions itself not as a direct replacement for existing glucose monitors, but as a new category of multi-metabolite, non-invasive sensing that could eventually subsume them. The competitive map is defined by the specific biomarker being measured and the invasiveness of the method.

For glucose monitoring alone, the field is dominated by established players with entrenched clinical and consumer distribution.

• Incumbent CGM leaders. Dexcom and Abbott's FreeStyle Libre dominate the continuous glucose monitoring market with FDA-cleared, minimally invasive sensor technology. Their primary advantage is regulatory clearance and a massive installed base in the diabetes management ecosystem, from patients to clinicians [PUBLIC].
• Non-invasive glucose challengers. A wave of startups is pursuing other non-invasive methods, such as optical spectroscopy (e.g., Know Labs), radiofrequency sensing, and breath analysis. These companies are Synex's most direct conceptual peers, though they use different underlying physics [PUBLIC].
• Adjacent metabolic substitutes. For ketone and lactate monitoring, the current standard involves finger-prick blood meters (e.g., Keto-Mojo) or consumer breath analyzers. These are single-parameter, often invasive or semi-invasive tools, creating a gap for a unified, needle-free platform [PUBLIC].

Synex's defensible edge today rests on its chosen technical path: miniaturized magnetic resonance spectroscopy (MRS). This is a capital-intensive, physics-heavy approach with high barriers to entry in hardware engineering and scientific validation. The company's early lead in assembling a team with NMR and product design expertise, evidenced by its patent-holding staff and recent senior engineering hires, is a tangible asset [Synex Medical, retrieved 2024]. This edge is durable only if Synex can continue to outpace competitors in translating lab-grade MRS into a reliable, consumer-safe device. The recent C$21.8 million Series A provides runway for this R&D, but the capital advantage is perishable against well-funded incumbents or new entrants [Osler, September 2024].

The company's most significant exposure is in the regulatory and commercial channels required for medical-grade claims. Dexcom and Abbott have spent decades building relationships with insurers, diabetes educators, and healthcare providers. Synex's initial consumer wearable concept may allow it to bypass some of this complexity initially, but to achieve its stated mission of "predictive medicine," it will eventually need to navigate the FDA and prove clinical utility, a process where incumbents have immense institutional knowledge. Furthermore, optical sensing competitors may achieve regulatory milestones for non-invasive glucose sensing first, potentially capturing early adopters and setting the standard for the category.

The most plausible 18-month scenario involves continued R&D progress by Synex and its peers, with no single winner yet emerging in non-invasive multi-metabolite monitoring. The "winner" in this period will be the company that publicly demonstrates a working prototype with compelling, third-party-validated accuracy data for at least one key metabolite like glucose. A "loser" scenario would involve any of the non-invasive contenders hitting a fundamental technical roadblock that forces a pivot, such as an inability to achieve necessary accuracy across diverse skin types and physiological conditions, which would validate the skepticism around the entire technical approach.

Data Accuracy: YELLOW -- Competitive analysis is based on public descriptions of the broader market segment; specific named competitor details and funding are not sourced for this landscape.

Opportunity

PUBLIC The prize for Synex Medical is the creation of a new, mass-market category of non-invasive, multi-parameter metabolic monitoring, moving beyond single-point glucose tracking to a continuous, comprehensive view of human biochemistry.

The headline opportunity is to become the foundational platform for predictive, personalized medicine by making real-time, multi-metabolite data accessible outside clinical settings. The reachable outcome is a consumer-grade wearable that replaces the need for periodic blood draws and single-use sensors, a market currently dominated by continuous glucose monitors (CGMs) for a single metric. This is more than aspirational because the company has demonstrated progress in miniaturizing magnetic resonance spectroscopy (MRS) technology, a proven clinical modality, into a portable form factor [Synex Medical, October 2020]. Their recent C$21.8 million Series A financing, described as oversubscribed, indicates investor confidence in the technical pathway [Osler, September 2024]. The core bet is that a non-invasive, multi-analyte device can command a premium and capture significant share from the established, yet invasive, monitoring markets.

Two primary growth scenarios outline how Synex could scale from a novel hardware developer to a category-defining health data company.

Scenario	What happens	Catalyst	Why it's plausible
Consumer Health Platform	The "One Ring" wearable and companion app achieve mainstream adoption among fitness enthusiasts, biohackers, and pre-diabetic consumers, creating a recurring revenue stream from device sales and subscription insights.	Successful commercial launch of the consumer wearable, validated by third-party accuracy studies and key opinion leader endorsements.	The company explicitly targets a consumer-oriented wearable and smartphone app for continuous health insights [Perplexity Sonar Pro Brief]. The market for health wearables is proven, and a multi-parameter device offers a clear feature differentiation.
Clinical & Research Tool	Synex's compact MRS device is adopted by clinics, research institutions, and pharmaceutical companies as a tool for continuous metabolic monitoring in trials and patient management, establishing a high-margin B2B business line.	A partnership with a major research hospital or life sciences company to validate the device for specific clinical endpoints.	The technology's foundation in magnetic resonance spectroscopy lends itself to clinical validation [Synex Medical]. The hiring of a Principal MRS Scientist suggests ongoing research and development aimed at scientific rigor [Synex Medical, retrieved 2024].

What compounding looks like for Synex is a data-driven flywheel. Early adoption, whether consumer or clinical, generates a proprietary dataset correlating real-time metabolite levels with health outcomes and behaviors. This dataset could improve the predictive algorithms within the app, enhancing the value proposition for users. In turn, better algorithms and demonstrated health correlations could strengthen regulatory claims and support expansion into insurance or employer wellness programs, creating a distribution lock-in. Evidence that this cycle is beginning is indirect but visible in the team's build-out, including roles focused on machine learning and data science [Synex Medical, retrieved 2024].

The size of the win can be framed by looking at established comparables. The market for continuous glucose monitoring alone is projected to reach over $20 billion globally by 2030, with dominant players like Dexcom achieving multi-billion dollar valuations. A device that monitors glucose plus lactate, ketones, and other metabolites could reasonably target a premium segment of that broader metabolic health market. If the consumer platform scenario plays out and Synex captures even a single-digit percentage of the expanding CGM and adjacent wellness markets, the company's valuation could reach the low billions of dollars (scenario, not a forecast). This potential is what underpins the venture-scale capital already committed to the technical challenge.

Data Accuracy: YELLOW -- Core opportunity thesis is supported by company statements and financing events, but specific market size projections and competitive win scenarios are extrapolated from the broader category.

Sources

PUBLIC

1. [Synex Medical] Synex Medical , https://synexmedical.com/

2. [TechCrunch, September 2024] Synex founder, once detained at the border with an 80-pound magnet, is building portable MRIs to test glucose | TechCrunch , https://techcrunch.com/2024/09/22/synex-founder-once-detained-at-the-border-with-a-80-pound-magnet-is-building-portable-mris-to-test-glucose/

3. [Synex Medical, October 2020] Synex Medical raises $5.25M in Seed Round to develop non-invasive blood monitor , https://synexmedical.medium.com/synex-medical-raises-5-25m-in-seed-round-to-develop-non-invasive-blood-monitor-3471b4e8c40

4. [Osler, September 2024] Osler advises Synex Medical on its C$21.8 million oversubscribed Series A financing , https://www.osler.com/en/about-us/representative-work/synex-medical-2/

5. [LinkedIn] Synex Medical | LinkedIn , https://www.linkedin.com/company/synexmedical

6. [Crunchbase, retrieved 2024] Synex Medical - Crunchbase Company Profile & Funding , https://www.crunchbase.com/organization/synex-medical

7. [Perplexity Sonar Pro Brief, retrieved 2024] Synex Medical , https://pitchbook.com/profiles/company/267583-87

8. [Grand View Research, 2024] Continuous Glucose Monitoring Market Size, Share & Trends Analysis Report , https://www.grandviewresearch.com/industry-analysis/continuous-glucose-monitoring-market

9. [Precedence Research, 2024] Wearable Medical Devices Market Size, Share, Growth, Trends, and Forecast 2024-2033 , https://www.precedenceresearch.com/wearable-medical-devices-market